Literature DB >> 15849770

Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance.

Samir K Ballas1, Margaret Lusardi.   

Abstract

The acute sickle cell painful episode is the most common cause of hospitalization of patients with sickle cell anemia. Its detailed clinical features and peri-discharge features are not well known. In order to determine the actual pattern of hospital admissions of patients with SS and the causes of frequent hospital readmissions and their prognostic significance, we conducted a prospective longitudinal and observation cohort study of all adult patients with sickle cell anemia admitted to Thomas Jefferson University Hospital between January 1998 and December 2002. Major outcome measures included the frequency, etiology, and prognostic significance of readmissions to the hospital within 1 week and 1 month after discharge. Incidence of mortality among patients during the study period was also determined. Analysis of the data showed that about 50% of hospital admissions for acute painful episodes were readmitted within 1 month after discharge, and about 16% of all admissions were within 1 week after discharge. The intensity of pain score decreased significantly during the first 4 days of hospital admission (P < 0.001) and then reached a plateau until discharge. The mean score of pain intensity was >7 throughout the hospital stay. Causes of hospital readmission included premature discharge, withdrawal syndrome, and recurrence of new acute episodes. Readmission within 1 week after discharge was associated with higher mortality than otherwise. This study shows that hospital readmission of adult patients with sickle cell anemia is common. It suggests that improvement is needed in the management of pain during hospitalization and at home after discharge. Patients who are readmitted frequently within 1 week of discharge have poor prognosis and require careful monitoring. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15849770     DOI: 10.1002/ajh.20336

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  73 in total

1.  Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.

Authors:  Gabriela Calhoun; Li Wang; Luis E F Almeida; Nicholas Kenyon; Nina Afsar; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado
Journal:  Eur J Pharmacol       Date:  2015-02-25       Impact factor: 4.432

2.  Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.

Authors:  Marilyn J Telen; Ted Wun; Timothy L McCavit; Laura M De Castro; Lakshmanan Krishnamurti; Sophie Lanzkron; Lewis L Hsu; Wally R Smith; Seungshin Rhee; John L Magnani; Helen Thackray
Journal:  Blood       Date:  2015-03-02       Impact factor: 22.113

3.  Review of Medication Therapy for the Prevention of Sickle Cell Crisis.

Authors:  Tanya R Riley; Angelo Boss; Dominique McClain; Treavor T Riley
Journal:  P T       Date:  2018-07

4.  Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS), a focus group and decision support tool development project.

Authors:  Paula Tanabe; Christopher Reddin; Victoria L Thornton; Knox H Todd; Ted Wun; John S Lyons
Journal:  Acad Emerg Med       Date:  2010-08       Impact factor: 3.451

5.  Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation.

Authors:  Amy Sobota; Dionne A Graham; Ellis J Neufeld; Matthew M Heeney
Journal:  Pediatr Blood Cancer       Date:  2011-06-14       Impact factor: 3.167

6.  Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.

Authors:  Sophie Lanzkron; C Patrick Carroll; Carlton Haywood
Journal:  Public Health Rep       Date:  2013 Mar-Apr       Impact factor: 2.792

7.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

8.  Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease.

Authors:  Melissa J Frei-Jones; Joshua J Field; Michael R DeBaun
Journal:  Pediatr Blood Cancer       Date:  2009-04       Impact factor: 3.167

9.  Patterns of opioid use in sickle cell disease.

Authors:  Jin Han; Santosh L Saraf; Xu Zhang; Michel Gowhari; Robert E Molokie; Joharah Hassan; Chaher Alhandalous; Shivi Jain; Jewel Younge; Taimur Abbasi; Roberto F Machado; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2016-08-08       Impact factor: 10.047

Review 10.  State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Authors:  Latika Puri; Kerri A Nottage; Jane S Hankins; Doralina L Anghelescu
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.